Bismuth Citrate CAS 813-93-4: Key Intermediate for GI Health Formulations
Bismuth Citrate, identified by CAS number 813-93-4, stands as a crucial compound within the pharmaceutical industry, particularly for formulations targeting gastrointestinal (GI) health. As a key intermediate, its precise chemical properties and consistent availability are vital for drug manufacturers worldwide.
The primary utility of Bismuth Citrate lies in its role as an active pharmaceutical ingredient (API) precursor or as a direct active component in medications aimed at treating a variety of digestive system ailments. Its well-documented antimicrobial and cytoprotective effects make it highly sought after for use in treatments for conditions such as peptic ulcers, gastritis, and infections caused by Helicobacter pylori. For R&D scientists and procurement managers, understanding these applications is fundamental when considering this ingredient.
When sourcing Bismuth Citrate, look for suppliers that emphasize purity and adherence to pharmaceutical standards. The typical specifications include a white powder appearance and a Bismuth content assay between 49% and 54%. Manufacturers often require these materials in substantial quantities, making the production capacity and reliability of the supplier critical factors. A manufacturer with a capacity of 300 metric tons per year, for instance, can accommodate large-scale production runs, ensuring continuity for your product line.
The commercial aspect of procuring Bismuth Citrate involves more than just the price; it requires a strategic partnership with a chemical supplier that understands the pharmaceutical sector’s demands. This includes robust quality control measures, timely delivery, and comprehensive documentation. For those looking to buy Bismuth Citrate in bulk, a competitive price point coupled with unwavering quality is a significant advantage. Companies seeking a trusted manufacturer in China can find reliable options that cater to international pharmaceutical markets.
The therapeutic benefits derived from Bismuth Citrate contribute to its sustained demand. Its ability to aid in the healing of stomach lining damage and to combat pathogenic bacteria like H. pylori solidifies its position as an essential pharmaceutical intermediate. Therefore, establishing a relationship with a reputable Bismuth Citrate supplier is a strategic move for any company dedicated to advancing gastrointestinal healthcare through effective pharmaceutical solutions.
Perspectives & Insights
Nano Explorer 01
“The primary utility of Bismuth Citrate lies in its role as an active pharmaceutical ingredient (API) precursor or as a direct active component in medications aimed at treating a variety of digestive system ailments.”
Data Catalyst One
“Its well-documented antimicrobial and cytoprotective effects make it highly sought after for use in treatments for conditions such as peptic ulcers, gastritis, and infections caused by Helicobacter pylori.”
Chem Thinker Labs
“For R&D scientists and procurement managers, understanding these applications is fundamental when considering this ingredient.”